AR065803A1 - Uso de un polipeptido de il- 18 humana y un anticuerpo anti- cd para preparar unmedicamento - Google Patents

Uso de un polipeptido de il- 18 humana y un anticuerpo anti- cd para preparar unmedicamento

Info

Publication number
AR065803A1
AR065803A1 ARP080101155A ARP080101155A AR065803A1 AR 065803 A1 AR065803 A1 AR 065803A1 AR P080101155 A ARP080101155 A AR P080101155A AR P080101155 A ARP080101155 A AR P080101155A AR 065803 A1 AR065803 A1 AR 065803A1
Authority
AR
Argentina
Prior art keywords
lymphoma
cell
leukemia
hodgkin
cells
Prior art date
Application number
ARP080101155A
Other languages
English (en)
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39788932&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR065803(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Publication of AR065803A1 publication Critical patent/AR065803A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3061—Blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Abstract

Uso de (i) un polipéptido de IL-18 humana (SEQ ID N°:16); y (ii) un anticuerpo anti-CD, tal como rituximab u ofatumumab para preparar un medicamento util para tratar o prevenir cánceres para uso simultáneo o secuencial en cualquier orden. El cáncerse selecciona entre el grupo consistente en NHL (linfoma no Hodgkin), incluyendo leucemia linfoblástica de células B/linfoma, neoplasmas de células B maduras, leucemia Iinfocítica cronica da células B (CLL)/Iinfoma linfocítico pequeno (SLL),leucemia proIinfocítica de células B, linfoma linfoplasmacítico, linfoma de células del manto (MCL), linfoma folicuIar (FL), incluyendo FL de bajo grado, de grado intermedio y de alto grado, linfoma del centro folicular cutáneo, linfoma de células Bde zona marginal (tipo MALT, tipo nodal y esplénico), leucemia de células pilosas, linfoma de células B grande difuso, linfoma de Burkitt, plasmacitoma, mieloma de células plasmáticas, trastorno linfoproliferativo posterior a un trasplante,macroglobulinemia de Waldenstrom linfoma anaplásico de células grandes (ALCL), y linfoma no Hodgkin de células T.
ARP080101155A 2007-03-23 2008-03-19 Uso de un polipeptido de il- 18 humana y un anticuerpo anti- cd para preparar unmedicamento AR065803A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US89685507P 2007-03-23 2007-03-23
US95200207P 2007-07-26 2007-07-26

Publications (1)

Publication Number Publication Date
AR065803A1 true AR065803A1 (es) 2009-07-01

Family

ID=39788932

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP080101155A AR065803A1 (es) 2007-03-23 2008-03-19 Uso de un polipeptido de il- 18 humana y un anticuerpo anti- cd para preparar unmedicamento
ARP080101195A AR065818A1 (es) 2007-03-23 2008-03-25 Metodos de tratamiento del cancer mediante administracion de combinaciones de il-18 humana

Family Applications After (1)

Application Number Title Priority Date Filing Date
ARP080101195A AR065818A1 (es) 2007-03-23 2008-03-25 Metodos de tratamiento del cancer mediante administracion de combinaciones de il-18 humana

Country Status (21)

Country Link
US (4) US20100111945A1 (es)
EP (3) EP2129398A4 (es)
JP (2) JP2010522239A (es)
KR (2) KR20100014530A (es)
CN (1) CN101678102A (es)
AR (2) AR065803A1 (es)
AU (2) AU2008231114A1 (es)
BR (2) BRPI0808943A2 (es)
CA (2) CA2681827A1 (es)
CL (2) CL2008000818A1 (es)
CR (2) CR10996A (es)
DO (2) DOP2009000208A (es)
EA (2) EA200970884A1 (es)
IL (2) IL200525A0 (es)
MA (2) MA31265B1 (es)
MX (2) MX2009010271A (es)
NZ (1) NZ579179A (es)
PE (2) PE20090190A1 (es)
SG (1) SG171674A1 (es)
TW (2) TW200906436A (es)
WO (2) WO2008118736A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ520392A (en) * 2000-02-10 2005-04-29 Abbott Lab Antibodies that bind human interleukin-18 and methods of making and using
US7968684B2 (en) 2003-11-12 2011-06-28 Abbott Laboratories IL-18 binding proteins
AR065803A1 (es) * 2007-03-23 2009-07-01 Smithkline Beecham Corp Uso de un polipeptido de il- 18 humana y un anticuerpo anti- cd para preparar unmedicamento
TW201302793A (zh) 2010-09-03 2013-01-16 Glaxo Group Ltd 新穎之抗原結合蛋白
MA47811A (fr) 2014-04-25 2019-06-19 Pf Medicament Kit comprenant un conjugué anticorps-médicament igf-1r et son utilisation pour le traitement du cancer
RU2685259C2 (ru) 2014-04-25 2019-04-17 Пьер Фабр Медикамент Конъюгат антитела и лекарственного средства и его применение для лечения рака
CN106687124B (zh) * 2014-08-07 2022-03-15 冈村春树 并用il-18与分子靶向抗体的癌治疗药
WO2016126615A1 (en) * 2015-02-03 2016-08-11 Armo Biosciences, Inc. Methods of using interleukin-10 for treating diseases and disorders
WO2022115946A1 (en) * 2020-12-02 2022-06-09 The Royal Institution For The Advancement Of Learning/Mcgill University Therapeutic applications of type 1 insulin-like growth factor (igf-1) receptor antagonists

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0692536B1 (en) 1994-07-14 2000-11-22 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo IFN-Y production inducing protein and monoclonal antibody of the same
TW581771B (en) 1994-11-15 2004-04-01 Hayashibara Biochem Lab Recombinant production of a polypeptide for inducing interferon-gamma production, and monoclonal antibody against the polypeptide
JP4004088B2 (ja) 1995-09-26 2007-11-07 株式会社林原生物化学研究所 免疫担当細胞においてインターフェロン−γの産生を誘導する蛋白質
US7135458B1 (en) * 1995-11-15 2006-11-14 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Interferon-γ inducing polypeptide, pharmaceutical composition thereof, monoclonal antibody thereto, and methods of use
US5680795A (en) 1995-07-05 1997-10-28 Norco Inc. Mechanical drive assembly incorporating counter-spring biassed radially-adjustable rollers
JP4024366B2 (ja) * 1996-11-29 2007-12-19 株式会社林原生物化学研究所 ポリペプチド
US6787132B1 (en) * 1997-12-04 2004-09-07 Yissum Research Development Company Of The Hebrew University Of Jerusalem Combined chemo-immunotherapy with liposomal drugs and cytokines
TWI227136B (en) * 1998-05-21 2005-02-01 Smithkline Beecham Corp Novel pharmaceutical composition for the prevention and/or treatment of cancer
AU2001280442B2 (en) 2000-06-15 2005-10-27 Smithkline Beecham Corporation Method for preparing a physiologically active il-18 polypeptide
US20020094323A1 (en) * 2000-10-12 2002-07-18 Kristoffer Hellstrand Methods and compositions for promoting the maturation of monocytes
WO2003068821A2 (en) * 2002-02-14 2003-08-21 Immunomedics, Inc. Anti-cd20 antibodies and fusion proteins thereof and methods of use
EP1485130A4 (en) * 2002-02-21 2006-11-22 Univ Duke REAGENTS AND TREATMENT PROCEDURES FOR AUTOIMMUNE DISEASES
ES2358645T3 (es) * 2002-09-16 2011-05-12 Agennix Incorporated Composiciones de lactoferrina y métodos de tratamiento de la úlcera diabética.
EP1558284B1 (en) * 2002-10-08 2013-09-11 Immunomedics, Inc. Combination therapy with naked class iii anti-cea monoclonal antibodies and therapeutic agents
EP2330130B1 (en) * 2002-10-17 2014-08-27 Genmab A/S Human monoclonal antibodies against CD20
US7534427B2 (en) * 2002-12-31 2009-05-19 Immunomedics, Inc. Immunotherapy of B cell malignancies and autoimmune diseases using unconjugated antibodies and conjugated antibodies and antibody combinations and fusion proteins
WO2004091517A2 (en) * 2003-04-15 2004-10-28 Smithkline Beecham Corporation Conjugates comprising human il-18 and substitution mutants thereof
WO2005018542A2 (en) * 2003-07-10 2005-03-03 Agennix Incorporated Use of lactoferrin in prophylaxis against infection and/or inflammation in immunosuppressed subjects
EP1648512A4 (en) * 2003-07-31 2009-01-21 Immunomedics Inc ANTI-CD19 ANTIBODIES
ES2357550T3 (es) * 2005-04-18 2011-04-27 Novo Nordisk A/S Variantes de la il-21.
CA2615846A1 (en) * 2005-07-21 2007-01-25 Genmab A/S Potency assays for antibody drug substance binding to an fc receptor
EP2368566A1 (en) * 2006-07-13 2011-09-28 ZymoGenetics, Inc. Interleukin 21 and tyrosine kinase inhibitor combination therapy
WO2008033499A2 (en) * 2006-09-14 2008-03-20 The Trustees Of The University Of Pennsylvania Modulation of regulatory t cells by human il-18
AR065803A1 (es) * 2007-03-23 2009-07-01 Smithkline Beecham Corp Uso de un polipeptido de il- 18 humana y un anticuerpo anti- cd para preparar unmedicamento

Also Published As

Publication number Publication date
KR20100015798A (ko) 2010-02-12
CA2681827A1 (en) 2008-10-02
EP2136841A4 (en) 2010-07-07
EP2338514A1 (en) 2011-06-29
IL200863A0 (en) 2010-05-17
EA200970885A1 (ru) 2010-02-26
JP2010522200A (ja) 2010-07-01
SG171674A1 (en) 2011-06-29
EP2129398A1 (en) 2009-12-09
BRPI0809079A2 (pt) 2019-03-06
CR10996A (es) 2009-11-12
EA200970884A1 (ru) 2010-04-30
AU2008231025A1 (en) 2008-10-02
CL2008000818A1 (es) 2008-09-26
TW200906436A (en) 2009-02-16
DOP2009000208A (es) 2010-03-31
MA31264B1 (fr) 2010-03-01
CA2681851A1 (en) 2008-10-02
DOP2009000220A (es) 2009-10-31
WO2008118736A1 (en) 2008-10-02
KR20100014530A (ko) 2010-02-10
WO2008118733A3 (en) 2008-11-27
US20100196310A1 (en) 2010-08-05
AU2008231114A1 (en) 2008-10-02
EP2136841A2 (en) 2009-12-30
US20090035258A1 (en) 2009-02-05
US20080274078A1 (en) 2008-11-06
WO2008118733A2 (en) 2008-10-02
CR11075A (es) 2010-03-22
US20100111945A1 (en) 2010-05-06
JP2010522239A (ja) 2010-07-01
MX2009010269A (es) 2009-10-12
CL2008000842A1 (es) 2008-10-17
MX2009010271A (es) 2009-10-12
AR065818A1 (es) 2009-07-01
NZ579179A (en) 2011-12-22
CN101678102A (zh) 2010-03-24
PE20090184A1 (es) 2009-03-22
PE20090190A1 (es) 2009-03-22
EP2129398A4 (en) 2010-04-21
BRPI0808943A2 (pt) 2014-08-26
MA31265B1 (fr) 2010-03-01
IL200525A0 (en) 2010-04-29
TW200904469A (en) 2009-02-01

Similar Documents

Publication Publication Date Title
AR065803A1 (es) Uso de un polipeptido de il- 18 humana y un anticuerpo anti- cd para preparar unmedicamento
ZA202005556B (en) Cartyrin compositions and methods for use
PE20190173A1 (es) Receptores de antigenos quimericos y celulas t y metodos de uso
EA202091333A1 (ru) Способы активации, модификации и экспансии t-клеток для лечения рака и связанных с ним злокачественных заболеваний
BR112013002079A2 (pt) modificadores do receptor de aril hidrocarboneto (ahr) como novos terapêuticos contra o câncer
CR20130593A (es) Uso del anticuerpo anti-cd19 inmunoconjugado con maitansinoide para el tratamiento del síntoma tumores de células b
CL2008003846A1 (es) Uso de compuestos derivados de 1,2,4-triazolo condensado con heterociclos, los cuales actuan como ligados del receptor de androgeno (ar); compuestos; proceso de preparacion; composicion farmaceutica y el uso de dichos compuestos para el tratamiento del cancer de prostata.
EA201390756A1 (ru) Модулирующие nk-клетки терапии и способы для лечения гематологических злокачественных заболеваний
MX2019000643A (es) Receptores de antigenos quimericos y metodos de uso.
EA200701094A1 (ru) Усовершенствованное лечение рака с применением агонистов tlr3
CL2012001387A1 (es) Anticuerpos murinos, humanizados o fragmentos de ellos anti-receptor epha2; conjugados citotoxicos; composiciones farmaceuticas que los contienen; secuencias nucleotidicas; vector; celula huesped e hibridomas que los producen y el uso de los anticuerpos en el tratamiento del cancer como en metodos de diagnostico. (divisional de sol. n° 2085-07)
EA201791843A3 (ru) Способы повышения эффективности folr1 терапии рака
UY31127A1 (es) Ligandos de oxiadazol del receptor metabotropico para el glutamato y su utilizacion como potenciadores - 841
DOP2010000037A (es) Anticuerpos humanos contra cd20 humano y metodo para utilizarlos
CL2012003745A1 (es) Compuestos derivados de aminopirazoloquinazolinas, como inhibidores frente a la actividad fosforilante del receptor igf-1 localizado en membranas celulares; preparacion farmaceutica que los contiene; y su uso en el tratamiento y/o prevencion de cancer, infecciones, enfermedades inflamatorias y autoinmunitarias.
BR112013005145A2 (pt) anticorpos anti-cxcl13 e métodos para seu uso
MY169771A (en) Systems, methods and compositions for optical stimulation of target cells
GT200600324A (es) Nuevos anticuerpos anti-igf-ir y usos de los mismos
PE20131111A1 (es) Clasificacion de material extraido
CO6382131A2 (es) Derivados de tieno [3,2-c]piridina como inhibidores de quinasas para el uso en el tratamiento del cáncer
AR083751A1 (es) Derivados de 1h-pirrolo[2,3-b]piridina y uso de los mismos en el tratamiento del cancer
AR116048A1 (es) Composiciones y métodos para reprogramar receptores de células t (tcr) usando proteínas de fusión
ECSP10010168A (es) Benzotiazolas como moduladores del receptor de ghrelina
AR089028A1 (es) Composiciones y metodos para el analisis de cancer de prostata
BR112015013260A2 (pt) uso de inibidores de telomerase para o tratamento de distúrbios mieloproliferativos e neoplasias mieloproliferativas

Legal Events

Date Code Title Description
FA Abandonment or withdrawal